Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.69 +0.79%

+$0.03 today

Market cap
$160.46M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.27M

Average 0.16M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$9.14M

FY 2025 · Annual

Investing Cash Flow

$5.44M

FY 2025 · Annual

-94.9% YoY

Financing Cash Flow

-$4.74M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.24M)(36.56M)5.53M(19.06M)64.02M
Depreciation & Amortization77K58K196K193K121K
Deferred Income Tax00007.91M
Stock-Based Compensation00005.99M
Change in Working Capital(1.32M)(943K)(2.7M)3.2M(1.91M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.06M(376K)(2.23M)3.53M1.13M
Other Working Capital(3.38M)(567K)(471K)(325K)(3.04M)
Other Non-Cash Items2.3M8.75M(13.32M)7.26M(85.28M)
Operating Cash Flow(21.18M)(28.7M)(10.3M)(8.41M)(9.15M)
Capital Expenditures(375K)(496K)(254K)(18K)(1.93M)
Acquisitions (Net)1.5M24K00(7.25M)
Purchases of Investments(53.82M)(154.41M)(190.92M)(55.76M)(88.51M)
Sales of Investments30.43M185.09M118.14M161.65M96.88M
Other Investing Activities(1K)2K0(60K)6.25M
Investing Cash Flow(22.26M)30.21M(73.04M)105.82M5.44M
Debt Repayment——49.55M(49.55M)0
Common Stock Issued101.39M11.56M2.43M00
Common Stock Repurchased000(2.48M)(4.74M)
Dividends Paid00000
Other Financing Activities000(2K)0
Financing Cash Flow101.39M11.56M51.98M(52.04M)(4.74M)
Effect of Forex Changes2K(49.85M)(54K)(4K)(30K)
Net Change in Cash57.95M(36.78M)(31.41M)45.37M(8.47M)
Free Cash Flow(21.56M)(29.2M)(10.55M)(8.43M)(11.08M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$64.0M
+ D&A$121.0K
+ Stock-Based Comp$6.0M
+ Deferred Tax$7.9M
- Working Capital-$1.9M
- Other Non-Cash-$85.3M
= Operating Cash Flow-$9.1M
- Capex-$1.9M
= Free Cash Flow-$11.1M

Analysis

FY2025 free cash flow is -$11.1M. FCF conversion is -17.3% of net income. Operating cash flow was -$9.1M, with capex of -$1.9M. The largest bridge item is Other Non-Cash at -$85.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026

Does ORMP generate free cash flow?

Oramed Pharmaceuticals Inc. (ORMP) generated -$11.08M of free cash flow in fiscal 2025.

How much operating cash flow does ORMP produce?

Operating cash flow was -$9.14M, before capital expenditures of $1.93M.